Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 33 results for ibrutinib

  1. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    7 January 2026

    Sections for TA1119

  2. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA677

  3. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  4. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  6. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  7. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  9. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

    Technology appraisal guidance
    Discontinued

  10. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued Reference number: GID-TA10382

    Technology appraisal guidance
    Discontinued

  11. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  12. Venetoclax for treating chronic lymphocytic leukaemia (TA796)

    Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    15 June 2022
    View recommendations

    Sections for TA796

  13. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  15. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued